Results 221 to 230 of about 82,153 (256)
Some of the next articles are maybe not open access.
Topic: AS08-Treatment/AS08g-Clinical trials - Phase II-III
Leukemia Research, 2021 P. Peterlin, P. Turlure, P. Chevallier, M.-P. Gourin, P.-Y. Dumas, S. Thepot, A. Berceanu, S. Park, M.-A. Hospital, T. Cluzeau, J.-M. Torregrossa-Diaz, L. Devron, R. Sapena, F. Chermat, S. Dimicoli-Salazar, P. Fenaux +15 more +4 more sourcesA clinical phase I/II trial of rhIL-4 applied topically in patients with oral squamous cell carcinomas to assess safety and therapeutic activity
Oncology Reports, 2005 Besides its immunoregulatory effects, interleukin-4 (IL-4) has growth inhibitory activity on cells from human solid tumors, and IL-4 receptors are present on tumor cells including cells from head and neck squamous cell carcinomas. We have conducted a phase I/II trial in patients with oral squamous cell carcinomas of T(4), N(+) (1 exception) stage to ...Richard, Werkmeister, Thomas, Fillies, Christoph, Gaertner, Ulrich, Joos, Wolfgang E, Berdel +4 moreopenaire +2 more sourcesTopical sirolimus therapy for cutaneous vascular anomalies: A randomized phase II clinical trial
The Journal of DermatologyAbstract The efficacy, safety, and optimal concentration of topical sirolimus gel for treatment of cutaneous lesions of vascular anomalies requires evaluation. This study was a multicenter, double‐blind, placebo‐controlled, parallel‐group, phase II randomized clinical trial.Masatoshi Jinnin, Toshio Shimokawa, Akiko Kishi, Nobukazu Hayashi, Michiko Nagahama, Akiharu Kubo, Michio Ozeki, Shuichi Shimada, Satoshi Fukushima, Tomotaka Kawabata, Tomoki Okuyama, Aki Okubo, Yumika Sawai, Ayato Hayashi, Mana Kurimoto‐Nishiguchi, Mariko Sakata, Kayo Kunimoto, Yuki Yamamoto +17 moreopenaire +2 more sourcesFinal report of PIMTO-MF clinical trial: multicenter, phase II trial for treatment of early MF with topical pimecrolimus
European Journal of Cancer, 2022 PL Ortiz-Romero, L Maroñas Jiménez, C Muniesa, T Estrach, O Servitje, R Fernández de Misa, F Gallardo, O San Martín, E Riveiro-Falkenbach, N García Díaz, R Vega, D Lora, C Postigo, B Jiménez, M Sánchez-Beato, JP Vaqué, JL Rodríguez Peralto, A Gómez de la Cámara, J De la Cruz, MA Piris Pinilla +19 moreopenaire +1 more sourceTopic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: PEVAZ: A PHASE II STUDY OF PEVONEDISTAT AND AZACITIDINE IN MDS AND MDS/MPN PATIENTS RELAPSED OR REFRACTORY TO DNMT INHIBITION (DNMTI)
Leukemia Research, 2023 J. Watts, B. Smith, T. Bradley, B. Skikne, J. Mendler, V. Klimek, A. Thomassen, T. Stopcyzinski, S.-C. Chen, F. Run, I. Anderson, A. Moncrief, S. Madhu, A. Sochacki, A. Kishtagari, S. Strickland, M. Byrne, G. Ayers, S. Mohan, T. Moyo, M. Savona +20 moreopenaire +1 more sourceTopic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: EFFICACY AND SAFETY OF ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN THE CMML SUBPOPULATION FROM PHASE 2 AND ASCERTAIN PHASE 3 STUDIES
Leukemia Research, 2023 M. Savona, J. Mccloskey, E. Griffiths, K. Yee, A. Zeidan, A. Al-Kali, H.J. Deeg, P. Patel, M. Sabloff, M.-M. Keating, N. Zhu, N. Gabrail, S. Fazal, J. Maly, O. Odenike, H. Kantarjian, A. Dezern, C. O’Connell, G. Roboz, L. Busque, R. Buckstein, H. Amin, J. Randhawa, B. Leber, K.-H. Dao, Y. Sano, B. Mirakhur, H. Keer, G. Garcia-Manero +28 moreopenaire +1 more sourceTopic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: SELECT-MDS-1 TRIAL IN PROGRESS: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAMIBAROTENE/AZACITIDINE VS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED (ND) ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS
Leukemia Research, 2023 Basak, G., Roth, D.A., Klimek, V., Jonasova, A., Marconi, G., Deeren, D., Volkert, A., Chisholm, J., Fenaux, P., Ofran, Y., Nagy, Z., Kelly, M., Hodgson, G., Geissler, K., Campelo, M., Krishnamurthy, P., Hu, B., Dezern, A., Lübbert, M. +18 moreopenaire +2 more sources
